Immuron FY26 net sales rise 6% to AUD 7.7 million

• Immuron posted record FY26 net sales of AUD 7.7 million, up 6% from the prior comparative period; second-half net sales rose 7%.
• FY26 net profit improved by AUD 1.4 million versus FY25; cash climbed AUD 6.2 million to AUD 9 million.
• Australia net sales rose 10% despite a one-off Travelan inventory reduction at Chemist Warehouse/Sigma; U.S. net sales increased 7% in AUD.
• IMM-529 received U.S. FDA IND clearance in November 2025; Pullan Consulting was engaged in July 2026 to support partnering.
• FY27 plan targets North America investment, with milestones including portfolio expansion, IMM-529 partnering progress, geographic expansion, improved profitability, lower cash burn.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280600PRIMZONEFULLFEED9817511) on August 28, 2026, and is solely responsible for the information contained therein.